Mga Batayang Estadistika
| CIK | 1785173 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to 89bio, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
April 24, 2025 Private & Confidential Francis Sarena Via Email and DocuSign Dear Mr. |
|
| August 8, 2025 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc |
|
| August 7, 2025 |
EX-99.1 Exhibit 99.1 89bio Reports Second Quarter 2025 Financial Results and Corporate Updates – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – ENTRUST Phase 3 topline data in severe hypertri |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, In |
|
| May 1, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 1, 2025 |
Exhibit 99.1 89bio Reports First Quarter 2025 Financial Results and Corporate Updates – Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe h |
|
| April 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 15, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 9, 2025 |
Exhibit 99.1 Powerful Science Meaningful Medicines Changing Lives Nasdaq: ETNB April 2025 Disclaimers This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in this pres |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 S-8 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE Form S-8 89bio, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity (1) Common Stock, par value $0.001 per share (“Common Stock”) to be issued pursuant to future awards |
|
| February 27, 2025 |
Exhibit 19.1 89bio, Inc. INSIDER TRADING POLICY (dated November 9, 2023) I. INTRODUCTION Federal and state laws prohibit buying, selling or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such material nonpublic information (“Material Nonpublic Information”) from disclosing t |
|
| February 27, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39122 89bio, Inc. (Ex |
|
| February 27, 2025 |
Exhibit 99.1 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST |
|
| February 13, 2025 |
Exhibit B CONTROL PERSON IDENTIFICATION Suvretta Capital Management, LLC is the relevant entity for which Aaron Cowen is the control person. |
|
| February 13, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 3, 2025 |
EX-99.1 2 ex-99-02032025100212.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 3, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States |
|
| January 29, 2025 |
Exhibit 4.1 89BIO, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: January 30, 2025 89bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Holder”), i |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 29, 2025 |
21,671,428 Shares of Common Stock Pre-funded Warrants to Purchase 6,900,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-272144 PROSPECTUS SUPPLEMENT (To Prospectus dated May 23, 2023) 21,671,428 Shares of Common Stock Pre-funded Warrants to Purchase 6,900,000 Shares of Common Stock We are offering 21,671,428 shares of our common stock, par value $0.001 per share, or, in lieu of common stock to certain investors that so choose, pre-funded warran |
|
| January 29, 2025 |
Exhibit 1.1 89BIO, INC. (a Delaware corporation) 21,671,428 Shares of Common Stock Pre-Funded Warrants to Purchase 6,900,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: January 28, 2025 89BIO, INC. (a Delaware corporation) 21,671,428 Shares of Common Stock Pre-Funded Warrants to Purchase 6,900,000 Shares of Common Stock UNDERWRITING AGREEMENT January 28, 2025 Goldman Sachs & Co. LLC Leeri |
|
| January 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly |
|
| January 27, 2025 |
Subject to Completion Preliminary Prospectus Supplement dated January 27, 2025 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-272144 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permi |
|
| January 13, 2025 |
Exhibit 99.1 89bio Provides Business Update and Outlook for 2025 – Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enro |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 18, 2024 |
EX-1 2 tm2428752d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 18, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange |
|
| November 18, 2024 |
ETNB / 89bio, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2428752d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchins |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga307422etnb11142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per sh |
|
| November 14, 2024 |
Exhibit 4.1 89BIO, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: [•], 2024 89bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Holder”), is entit |
|
| November 14, 2024 |
ETNB / 89bio, Inc. / RTW INVESTMENTS, LP - 89BIO, INC. Passive Investment SC 13G/A 1 p24-3259sc13ga.htm 89BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate b |
|
| November 14, 2024 |
Exhibit 1.1 89BIO, INC. (a Delaware corporation) 11,455,882 Shares of Common Stock Pre-Funded Warrants to Purchase 3,250,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: November 12, 2024 89BIO, INC. (a Delaware corporation) 11,455,882 Shares of Common Stock Pre-Funded Warrants to Purchase 3,250,000 Shares of Common Stock UNDERWRITING AGREEMENT November 12, 2024 Goldman Sachs & Co. LLC Lee |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 13, 2024 |
11,455,882 Shares of Common Stock Pre-funded Warrants to Purchase 3,250,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-272144 PROSPECTUS SUPPLEMENT (To Prospectus dated May 23, 2023) 11,455,882 Shares of Common Stock Pre-funded Warrants to Purchase 3,250,000 Shares of Common Stock We are offering 11,455,882 shares of our common stock, par value $0.001 per share, or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 3,2 |
|
| November 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Regi |
|
| November 12, 2024 |
Subject to Completion Preliminary Prospectus Supplement dated November 12, 2024 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-272144 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permi |
|
| November 7, 2024 |
Amended and Restated 2023 Inducement Plan. 89BIO, INC. AMENDED AND RESTATED 2023 INDUCEMENT PLAN Originally ADOPTED BY THE BOARD: February 9, 2023 Amended and Restated by the Board: September 23, 2024 1. GENERAL. (a) Eligible Award Recipients. New Employees are eligible to receive Awards as a material inducement to the commencement of employment within the meaning of the Listing Rule . (b) Available Awards. This Plan provides for the grant |
|
| November 7, 2024 |
Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. July 31, 2024 Francis Sarena [***] Via Email Dear Mr. Sarena, We are pleased to offer you the position of Chief Ope |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio |
|
| November 7, 2024 |
Office Sublease by and between 89bio, Inc. and Sender, Inc., dated as of October 20, 2023. Exhibit 10.2 SUBLEASE BETWEEN SENDER, INC., a Delaware corporation AND 89BIO, INC., a Delaware corporation 655 MONTGOMERY STREET SAN FRANCISCO, CALIFORNIA 94111 Suite 1500 SUBLEASE THIS SUBLEASE (“Sublease”) is entered into as of October 20, 2023 (the “Effective Date”), by and between SENDER, INC., a Delaware corporation, d/b/a Sendoso (“Sublandlord”), and 89BIO, INC., a Delaware corporation (“Sub |
|
| November 7, 2024 |
Exhibit 99.1 89bio Reports Third Quarter 2024 Financial Results and Corporate Updates – The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials – – Topline data from the Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG) are expe |
|
| November 7, 2024 |
Exhibit 10.3 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment |
|
| November 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Comm |
|
| October 17, 2024 |
ETNB / 89bio, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 89bioInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 89BIO INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 282559103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| October 17, 2024 |
ETNB / 89bio, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1150448313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) February 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| October 3, 2024 |
EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, PURSUANT TO AN EXEMPTION FROM REGISTRATIO |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 7, 2024 |
89bio Appoints Francis Sarena as Chief Operating Officer Exhibit 99.1 89bio Appoints Francis Sarena as Chief Operating Officer SAN FRANCISCO, August 7, 2024 (GLOBE NEWSWIRE) – 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, ef |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 7, 2024 |
ETNB / 89bio, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, Address |
|
| August 5, 2024 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 5, 2024 |
EX-99.1 Exhibit 99.1 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates –The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients– –Phase 3 ENTRUST trial for patients with severe hypertriglyceridemia ( |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc |
|
| August 5, 2024 |
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors EX-99.2 Exhibit 99.2 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors SAN FRANCISCO, August 5, 2024 (GLOBE NEWSWIRE) – 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to it |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 9, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, In |
|
| May 9, 2024 |
Exhibit 99.1 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update –Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients– –Expect to initiate ENLIGHTEN-Cirrhosis trial this quarter in MASH patients with compensated cirrhosis (F4)– –Granted Priority Medicines (PRIME) status from the European M |
|
| April 17, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 17, 2024 |
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors EX-99.1 Exhibit 99.1 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) – 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 8, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 S-8 As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 8, 2024 |
EX-FILING FEES Exhibit 107.1 CALCULATION OF FILING FEE TABLE Form S-8 89bio, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share To be issued pursuant to future awards |
|
| March 6, 2024 |
ETNB / 89bio, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm248164d2sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39122 89bio, Inc. (Ex |
|
| March 1, 2024 |
Incentive Compensation Clawback Policy Exhibit 97.1 INCENTIVE COMPENSATION CLAWBACK POLICY Recoupment of Incentive-Based Compensation It is the policy of 89bio, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non- compliance with any financial reporting requirement under the federal securities laws (including any such correction t |
|
| March 1, 2024 |
Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our second amended and restated certificate of incorporation (as am |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-39122 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition R |
|
| February 29, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 29, 2024 |
Exhibit 99.1 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates – Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively – – Long-term data from Phase 2b ENLIVEN trial demonstrated sustained benefits of pegozafermin at week 48 in patients with adva |
|
| February 14, 2024 |
ETNB / 89bio, Inc. / Cormorant Asset Management, LP - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* 89bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 282559103 (CUSIP Number) December 19, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 14, 2024 |
ETNB / 89bio, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-etnb123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, |
|
| February 14, 2024 |
ETNB / 89bio, Inc. / RTW INVESTMENTS, LP - 89BIO, INC. Passive Investment SC 13G 1 p24-0711sc13g.htm 89BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to d |
|
| February 13, 2024 |
ETNB / 89bio, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 7, 2024 |
ETNB / 89bio, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - 89BIO, INC. Passive Investment SC 13G/A 1 p24-0378sc13ga.htm 89BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* 89Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate bo |
|
| December 13, 2023 |
ETNB / 89bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* 89BIO, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, Address a |
|
| December 8, 2023 |
Exhibit 4.1 89BIO, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: December 11, 2023 89bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Holder”), |
|
| December 8, 2023 |
15,135,135 Shares of Common Stock Pre-funded Warrants to Purchase 1,081,081 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-272144 PROSPECTUS SUPPLEMENT (To Prospectus dated May 23, 2023) 15,135,135 Shares of Common Stock Pre-funded Warrants to Purchase 1,081,081 Shares of Common Stock We are offering 15,135,135 shares of our common stock, par value $0.001 per share, or, in lieu of common stock to a certain investor, pre-funded warrants to purchase |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 8, 2023 |
Exhibit 1.1 89BIO, INC. (a Delaware corporation) 15,135,135 Shares of Common Stock Pre-Funded Warrants to Purchase 1,081,081 Shares of Common Stock UNDERWRITING AGREEMENT Dated: December 6, 2023 89BIO, INC. (a Delaware corporation) 15,135,135 Shares of Common Stock Pre-Funded Warrants to Purchase 1,081,081 Shares of Common Stock UNDERWRITING AGREEMENT December 6, 2023 BofA Securities, Inc. Leerink |
|
| December 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Regi |
|
| December 6, 2023 |
Subject to Completion Preliminary Prospectus Supplement dated December 6, 2023 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-272144 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permi |
|
| December 6, 2023 |
EX-99.1 Exhibit 99.1 Powerful Science Meaningful Medicines Changing Lives Nasdaq: ETNB December 2023 Disclaimers This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included i |
|
| December 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 4, 2023 |
EX-99.1 Exhibit 99.1 89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 —Alignment reached on key elements of the NASH development strategy, including accelerated approval pathway for both F4 and F2-F3 NASH patients using histology— —Outcomes trial in F4 cirrhotic NASH patient |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 27, 2023 |
Exhibit 99.1 89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) —Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injury/inflammation and fibrosis in NASH patients with fibrosis sta |
|
| November 14, 2023 |
EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF 89bio, Inc. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of 89bio, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). Section 1.2 Other Off |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 9, 2023 |
Exhibit 99.1 89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates –Pegozafermin granted Breakthrough Therapy Designation (BTD) for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis– –Feedback from regulatory agencies on pegozafermin Phase 3 development program in NASH expected this quarter– –Data from ENLIVEN in patients with cirrhotic (F4) NASH will b |
|
| October 30, 2023 |
ETNB / 89bio Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G 1 d1084461513-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) October 18, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 11, 2023 |
ETNB / 89bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* 89BIO, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, Address a |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc |
|
| August 9, 2023 |
EX-99.1 Exhibit 99.1 89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Published data from ENLIVEN Phase 2b trial of pegozafermin in NASH in The New England Journal of Medicine; presented the data in a late-breaker session at the EASL International Liver Congress – – Discussions with regulatory agencies regarding Phase 3 NASH program are planned for the second hal |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 9, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 89BIO, INC. 89bio, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name of the Corporation is 89bio, Inc. The original Certificate of Incorporation of |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 23, 2023 |
As filed with the Securities and Exchange Commission on May 23, 2023. S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 23, 2023. |
|
| May 23, 2023 |
EX-FILING FEES 5 d446909dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering price Per Unit Maximum Aggregate Offering Price Fee Rate |
|
| May 23, 2023 |
EX-4.2 Exhibit 4.2 89BIO, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314(a) 4. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc. |
|
| May 8, 2023 |
Exhibit 10.4 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. MASTER SERVICES AGREEMENT This Master Services Agreement (the “Agreement”) is entered into as of February 10th, 2023 (the “Effective Date”) by and between 89BIO, INC., a Dela |
|
| May 4, 2023 |
EX-99.1 Exhibit 99.1 89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update – Positive topline results from ENLIVEN Phase 2b trial of pegozafermin in NASH demonstrated high statistical significance on both primary histology endpoints supporting advancement to Phase 3; discussions with regulatory agencies planned for the second half of 2023 – – SHTG Phase 3 trial expected |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 25, 2023 |
Power of Attorney (included on signature page). S-3ASR Table of Contents As filed with the Securities and Exchange Commission on April 25, 2023 Registration No. |
|
| April 25, 2023 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables FORM S-3 (Form Type) 89bio, Inc. |
|
| April 24, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 24, 2023 |
Definitive Proxy Statement on Schedule 14A DEF 14A 1 d484374ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 14, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 30, 2023 |
ETNB / 89bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* 89BIO, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter Kolchinsky (N |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 28, 2023 |
89bio, Inc. Underwriting Agreement EX-1.1 Exhibit 1.1 89BIO, INC. (a Delaware corporation) 16,923,077 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 23, 2023 89BIO, INC. (a Delaware corporation) 16,923,077 Shares of Common Stock UNDERWRITING AGREEMENT March 23, 2023 BofA Securities, Inc. SVB Securities LLC Evercore Group L.L.C. as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New |
|
| March 27, 2023 |
16,923,077 Shares of Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-269471 PROSPECTUS SUPPLEMENT (To Prospectus dated February 14, 2023) 16,923,077 Shares of Common Stock We are offering 16,923,077 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and the accompanying prospectus. The public offering price for each share of common stock is $16. |
|
| March 24, 2023 |
ETNB / 89bio Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5)* Under the Securities Exchange Act of 1934 89bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 282559103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VI LLC 601 Lexington Avenue, 54th Floor New York, NY 1 |
|
| March 24, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| March 22, 2023 |
EX-99.1 Exhibit 99.1 89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks - 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH reso |
|
| March 22, 2023 |
EX-99.2 Powerful Science Meaningful Medicines Changing Lives Pegozafermin Phase 2b (ENLIVEN) Topline Results in Nonalcoholic Steatohepatitis (NASH) Nasdaq: ETNB Exhibit 99.2 Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertaintie |
|
| March 22, 2023 |
Subject to Completion Preliminary Prospectus Supplement dated March 22, 2023 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-269471 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 15, 2023 |
EX-99.3 Exhibit 99.3 89BIO, INC. 2023 INDUCEMENT PLAN ADOPTED BY THE BOARD: February 9, 2023 1. GENERAL. (a) Eligible Award Recipients. New Employees are eligible to receive Awards as a material inducement to the commencement of employment within the meaning of the Listing Rule. (b) Available Awards. This Plan provides for the grant of the following Awards: (i) Nonstatutory Stock Options; (ii) Sto |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 S-8 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our second amended and restated certificate of incorporation (the “ |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39122 89bio, Inc. (Ex |
|
| March 15, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 89bio, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share To be issued pursuant to future awards unde |
|
| March 10, 2023 |
EX-99.1 Exhibit 99.1 89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update – Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the second quarter of 2023 – – Published results of Phas |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 16, 2023 |
Up to $150,000,000 Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-269471 PROSPECTUS SUPPLEMENT (To prospectus dated February 14, 2023) Up to $150,000,000 Common Stock We previously entered into a sales agreement (as amended, the “sales agreement”) with SVB Securities LLC (“SVB Securities”) and Cantor Fitzgerald & Co. (“Cantor” and together with SVB Securities, the “Sales Agents”) relat |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 16, 2023 |
Exhibit 1.2 AMENDMENT NO. 1 TO THE SALES AGREEMENT February 15, 2023 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 CANTOR FITZGERALD & CO. 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement (this “Amendment”) is entered into as of the date first written above by 89bio, Inc., a Delaware corporation (the “C |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 15, 2023 |
Nasdaq: ETNB Powerful Science Meaningful Medicines Changing Lives February 2023 Exhibit 99. |
|
| February 14, 2023 |
ETNB / 89bio Inc / Longitude Capital Partners III, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) 89BIO, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 282559103 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854-5 |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, |
|
| February 14, 2023 |
ETNB / 89bio Inc / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-etnb123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 89bio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 10, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) 89bio, Inc. |
|
| February 10, 2023 |
As filed with the Securities and Exchange Commission on February 10, 2023 S-3/A As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. |
|
| February 10, 2023 |
89BIO, INC. 142 Sansome Street, 2nd Floor San Francisco, CA 94104 CORRESP 1 filename1.htm 89BIO, INC. 142 Sansome Street, 2nd Floor San Francisco, CA 94104 VIA EDGAR February 10, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: 89bio, Inc. Registration Statement on Form S-3 (File No. 333-269471) To Whom it May Concern: Pursuant to Rule 461 under the Securit |
|
| February 9, 2023 |
ETNB / 89bio Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. Passive Investment SC 13G/A 1 p23-0741sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 89Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designa |
|
| February 2, 2023 |
EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, PURSUANT TO AN EXEMPTION FROM REGISTRATIO |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023 (January 4, 2023) 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (C |
|
| January 31, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) 89bio, Inc. |
|
| January 31, 2023 |
As filed with the Securities and Exchange Commission on January 30, 2023. S-3 Table of Contents As filed with the Securities and Exchange Commission on January 30, 2023. |
|
| January 31, 2023 |
EX-4.2 Exhibit 4.2 89BIO, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314(a) 4. |
|
| January 26, 2023 |
ETNB / 89bio Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment SC 13D/A 1 ss1707982sc13da.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* 89bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 282559103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VI LLC |
|
| January 26, 2023 |
EX-99.1 2 ss1707982ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 4 to Schedule 13D, dated January 24, 2023, with respect to the ordinary shares of 89bio, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the u |
|
| January 6, 2023 |
EX-10.1 2 d445245dex101.htm EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of January 4, 2023 (the “Closing Date”) is entered into among 89BIO, INC., a Delaware corporation (“Parent”, and in its capacity as representative of any Borrowers hereunder from time to |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 29, 2022 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of December 29, 2022, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file wit |
|
| December 29, 2022 |
ETNB / 89bio Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 89bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 282559103 (CUSIP Number) December 19, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 10, 2022 |
Exhibit 10.1 KING & CO. INVESTMENT MANAGEMENT INC. SECOND AMENDMENT TO OFFICE LEASE KINGS BUILDING 142 SANSOME STREET, SAN FRANCISCO This SECOND AMENDMENT TO OFFICE LEASE is made as of this 31st day of August 2022, between King Family Irrevocable Trust, as Landlord, and 89bio, Inc., a Delaware Corporation, as Tenant. RECITALS: Landlord and Tenant entered into that certain Office Lease dated as of |
|
| November 10, 2022 |
Exhibit 99.1 89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update -Completed enrollment in ENLIVEN Phase 2b NASH trial with topline data expected in the first quarter of 2023- -Presented additional post-hoc exploratory analyses from the Phase 1b/2a NASH study of pegozafermin at AASLD The Liver Meeting? 2022- -Reported additional positive data from ENTRIGUE Phase 2 trial |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc. |
|
| October 21, 2022 |
ETNB / 89bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* 89BIO, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter Kolchinsky (N |
|
| August 12, 2022 |
ETNB / 89bio Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - 89BIO, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 89Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) July 29, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc. |
|
| August 11, 2022 |
Exhibit 99.1 89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 - - ENTRIGUE data to be presented as a late-breaker at European Society of Cardiology Congress 2022 - - ENLIVEN Phase 2b |
|
| July 11, 2022 |
ETNB / 89bio Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) June 29, 2022 |
|
| July 11, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated July 11, 2022 with respect to the Common Stock, $0.001 par value per share, of 89bio, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisio |
|
| July 8, 2022 |
ETNB / 89bio Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 6, 2022 |
ETNB / 89bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| July 6, 2022 |
ETNB / 89bio Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 5, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| July 5, 2022 |
ETNB / 89bio Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* 89bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 282559103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VI LLC 601 Lexington Avenue, 54th Floor New York, NY 1 |
|
| July 1, 2022 |
89bio, Inc. Underwriting Agreement EX-1.1 2 d376547dex11.htm EX-1.1 Exhibit 1.1 89BIO, INC. (a Delaware corporation) 18,675,466 Shares of Common Stock 7,944,252 Pre-Funded Warrants to Purchase 7,944,252 Shares of Common Stock 26,619,718 Common Warrants to Purchase 13,309,859 Shares of Common Stock UNDERWRITING AGREEMENT Dated: June 28, 2022 89BIO, INC. (a Delaware corporation) 18,675,466 Shares of Common Stock 7,944,252 Pre-Funded |
|
| July 1, 2022 |
Exhibit 4.2 89BIO, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [?] (subject to adjustment) Warrant No. [?] Original Issue Date: July 1, 2022 89bio, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its permitted registered assigns (the ?Holder?), is en |
|
| July 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 1, 2022 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT 89bio, Inc. Warrant Shares: Issue Date: July 1, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Issue Date?) and on or prior |
|
| June 30, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254684 PROSPECTUS SUPPLEMENT (To prospectus dated April 23, 2021) 18,675,466 Shares of Common Stock Pre-funded Warrants to Purchase 7,944,252 Shares of Common Stock Warrants to Purchase 13,309,859 Shares of Common Stock We are offering 18,675,466 shares of our common stock, par value $0.001 per share, or, in lieu of common sto |
|
| June 28, 2022 |
Exhibit 99.1 89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) - Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on backgrou |
|
| June 28, 2022 |
Nasdaq: ETNB Powerful Science Meaningful Medicines Changing Lives Pegozafermin Phase 2 (ENTRIGUE) Topline Results in Severe Hypertriglyceridemia (SHTG) Exhibit 99. |
|
| June 28, 2022 |
Subject to Completion Preliminary Prospectus Supplement dated June 28, 2022 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254684 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permi |
|
| June 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 10, 2022 |
ETNB / 89bio Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* 89bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 282559103 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| June 7, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc. |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 11, 2022 |
Exhibit 99.1 89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update - ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia (SHTG) patients remains on track with topline data expected in the second quarter of 2022 - - ENLIVEN Phase 2b NASH trial enrollment completion expected in the third quarter of 2022 followed by topline data in the first half of 2023 - |
|
| April 14, 2022 |
DEF 14A 1 etnb-def14a20220601.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 14, 2022 |
DEFA14A 1 etnb-defa14a20220601.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 24, 2022 |
Exhibit 99.1 89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH - - ENLIVEN Phase 2b NASH trial on track for topline data in first half of 2023 ? - Closed en |
|
| March 24, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 89bio, Inc. Table 1 ? Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share 457(c); 457(h) To be issued pursuant to future awards under |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39122 89bio, Inc. (Ex |
|
| March 24, 2022 |
As filed with the Securities and Exchange Commission on March 24, 2022 As filed with the Securities and Exchange Commission on March 24, 2022 Registration No. |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 24, 2022 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our second amended and restated certificate of incorporation (the ? |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) ( |
|
| March 4, 2022 |
89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors Exhibit 99.1 89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors SAN FRANCISCO, February 24, 2022 (GLOBE NEWSWIRE) ? 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E. Morrey Atki |
|
| February 24, 2022 |
89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors Exhibit 99.1 89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors SAN FRANCISCO, February 24, 2022 (GLOBE NEWSWIRE) ? 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E. Morrey Atki |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 14, 2022 |
ETNB / 89bio Inc / Nussbaum Ran - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) (Rule 13d-102) Under the Securities Exchange Act of 1934 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 7, 2022 |
ETNB / 89bio Inc / Longitude Capital Partners III, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) 89BIO, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 282559103 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854-5 |
|
| January 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2022 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 24, 2022 |
Exhibit 99.2 Pegozafermin (formerly BIO89-100) Phase 1b/2a NASH Histology Cohort Topline Results Nasdaq: ETNB January 24, 2022 Disclaimer This presentation contains ?forward-looking statements? within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, |
|
| January 24, 2022 |
Exhibit 99.1 89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH ? 63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and fibrosis improvement (26%) ? Robust changes on mu |
|
| January 10, 2022 |
ETNB / 89bio Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* 89bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 12, 2021 |
89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update SAN FRANCISCO, November 11, 2021 (GLOBE NEWSWIRE)?89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter e |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc. |
|
| November 12, 2021 |
KING & CO. investment management inc. FIRST AMENDMENT TO OFFICE LEASE KINGS BUILDING 142 SANSOME STREET, SAN FRANCISCO This FIRST AMENDMENT TO OFFICE LEASE is made as of this 27th day of July 2021, between King Family Irrevocable Trust, as Landlord, and 89bio, Inc., a Delaware Corporation, as Tenant. RECITALS: Landlord and Tenant entered into that certain Office Lease dated as of December 5, 2019 |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 3, 2021 |
89bio Announces Appointment of Kathy LaPorte to its Board of Directors Exhibit 99.1 89bio Announces Appointment of Kathy LaPorte to its Board of Directors SAN FRANCISCO, November 3, 2021 (GLOBE NEWSWIRE) ? 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board o |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc. |
|
| August 12, 2021 |
EX-99.1 2 d120752dex991.htm EX-99.1 Exhibit 99.1 89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Initiated Phase 2b ENLIVEN trial in NASH patients - - Completed enrollment in NASH histology cohort with topline data expected by year-end 2021 - SAN FRANCISCO, August 12, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 10, 2021 |
Nasdaq: ETNB Powerful Science Meaningful Medicines Changing Lives June 2021 Exhibit 99. |
|
| June 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 4, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 4, 2021 |
Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of May 28, 2021, by and between SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (?Bank? or ?SVB?), as collateral agent (in such capacity, ?Collateral Agent?), the Lenders listed on Sche |
|
| June 4, 2021 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* 89bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) RA Capital Manag |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 14, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of March 30, 2021, by and between SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (?Bank? or ?SVB?), as collateral agent (in such capacity, ?Collateral Agent?), the Lenders listed on Sc |
|
| May 14, 2021 |
Exhibit 10.2 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of April 30, 2021, by and between SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (?Bank? or ?SVB?), as collateral agent (in such capacity, ?Collateral Agent?), the Lenders listed on |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc. |
|
| May 13, 2021 |
Exhibit 99.1 89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update - ENLIVEN Phase 2b trial in NASH expected to be initiated in 2Q21 - SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE) ? 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 21, 2021 |
89BIO, INC. 142 Sansome Street, 2nd Floor San Francisco, CA 94104 89BIO, INC. 142 Sansome Street, 2nd Floor San Francisco, CA 94104 VIA EDGAR April 21, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: 89bio, Inc. Registration Statement on Form S-3 (File No. 333-254684) To Whom it May Concern: Pursuant to Rule 461 under the Securities Act of 1933, as amended |
|
| April 15, 2021 |
DEFA14A 1 etnb-defa14a20210602.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 25, 2021 |
As filed with the Securities and Exchange Commission on March 25, 2021 Registration No. |
|
| March 25, 2021 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our second amended and restated certificate of incorporation (the ? |
|
| March 25, 2021 |
Exhibit 4.4 89BIO, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314(a) 4.03; 12. |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39122 89bio, Inc. (Ex |
|
| March 25, 2021 |
Exhibit 1.2 89bio, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT March 25, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 CANTOR FITZGERALD & CO. 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: 89bio, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Leerink LLC and Canto |
|
| March 25, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 25, 2021. |
|
| March 24, 2021 |
EX-99.1 2 d318413dex991.htm EX-99.1 Exhibit 99.1 89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 - - NASH histology cohort topline data expected by YE21 - - Phase 2 SHTG trial (ENTRIGUE) expected to report topline data in 2H21 - SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) - 89bio, Inc. |
|
| March 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 89bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39122 36-4946844 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 9, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) (Rule 13d-102) Under the Securities Exchange Act of 1934 89bio Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* 89bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 282559103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 25, 2020 |
ETNB / 89bio, Inc. / Longitude Capital Partners III, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) 89BIO, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 282559103 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854-5 |
|
| November 13, 2020 |
Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of 89bio, Inc. (the “Company”), is to provide a compensation package that enables the Company to attract and retain high-caliber directors and aligns their interests with the interests of the Company’s stockholders. 1. ELIGIBILITY The Policy applies to all members of |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39122 89bio, Inc. |
